Please assess the completion status of the following clinical trial:

Trial Title: Loop Duodenal Switch Surgery in Morbidly Obese Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. The subject must be 18-70 years of age at time of enrollment.~2. The subject must be willing and able to participate in the study procedures and to understand and sign the informed consent.~3. The subject is under consideration for surgery for obesity or metabolic disease and elects to undergo a primary loop duodenal switch procedure or as a conversion procedure for failed, sustained weight loss after a sleeve gastrectomy or laparoscopic adjustable gastric band performed more than 12 months prior to time of evaluation.~4. The subject has a BMI of greater than or equal to 40 kg/m2 at time of surgical consultation.~Exclusion Criteria:~1. Subjects under 18 years of age or older than 70 years of age.~2. Subject is not willing or able to participate in the study procedures and understand the informed consent.~3. The subject wishes to under a different bariatric procedure other than the loop duodenal switch.~4. The subject has a BMI of less than 40 kg/m2 at the time of surgical consultation.~5. Any female subject who is pregnant, or is actively breast-feeding~6. Any subject who is considered to be part of a vulnerable population (eg. prisoners or those with psychological concerns or those without sufficient mental capacity)~7. The procedure is an emergency procedure~8. The subject is unable to unwilling to comply with the study requirements or follow-up schedule.~9. The subject has comorbidities which, in the opinion of the investigator, will not be appropriate for the study (eg. severe cardiovascular disease or history of gastrointestinal malignancy, history of upper GI gastric surgery, history of intestinal surgery, open cholecystectomy, immunosuppression, and non-ambulatory).~10. The subject has an estimated life expectancy of less than 6 months.~11. The subject has participated in an investigational drug or device research study within 30 days of enrollment.~12. The subject's insurance company does not cover a duodenal switch operation as treatment for morbid obesity.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).